Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Venmax Drugs & Pharmaceuticals's Net Margin % or its related term are showing as below:
BOM:531015'
s Net Margin % Range Over the Past 10 Years
Min: -515.39 Med: -77.36 Max: 3.09
Current: 2.51
BOM:531015's Net Margin % is ranked worse than 59.21% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.47
vs BOM:531015: 2.51
Venmax Drugs & Pharmaceuticals (BOM:531015) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Venmax Drugs & Pharmaceuticals Net Margin % Related Terms
Venmax Drugs & Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Venmax Drugs & Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venmax Drugs & Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venmax Drugs & Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Venmax Drugs & Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venmax Drugs & Pharmaceuticals (BOM:531015) has a Net Margin % of 2.72% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Venmax Drugs & Pharmaceuticals and its competitors. According to the industry distribution chart, Venmax Drugs & Pharmaceuticals ranks #569 out of 961 companies in the Drug Manufacturers industry, placing it in the top 59.2%.
Is Venmax Drugs & Pharmaceuticals' Net Margin % too high?
Venmax Drugs & Pharmaceuticals' current Net Margin % is 2.72%. The Drug Manufacturers industry median Net Margin % is 5.47. Venmax Drugs & Pharmaceuticals' value of 2.72% is 50.3% below this industry median. Based on the distribution chart, Venmax Drugs & Pharmaceuticals ranks #569 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Venmax Drugs & Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Venmax Drugs & Pharmaceuticals' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Venmax Drugs & Pharmaceuticals ranks #569 out of 961 companies for Net Margin %. This places Venmax Drugs & Pharmaceuticals in the lower half of its industry. The industry median Net Margin % is 5.47. Venmax Drugs & Pharmaceuticals' value of 2.72% is 50.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.47, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venmax Drugs & Pharmaceuticals's current Net Margin % of 2.72% is 50.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Venmax Drugs & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venmax Drugs & Pharmaceuticals's current Net Margin % is 2.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venmax Drugs & Pharmaceuticals stock overvalued right now?
Venmax Drugs & Pharmaceuticals (BOM:531015) has a current Net Margin % of 2.72%. The current Net Margin % is 2.72% and 50.3% below the Drug Manufacturers industry median of 5.47. Venmax Drugs & Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Venmax Drugs & Pharmaceuticals (BOM:531015), the current Net Margin % is 2.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Venmax Drugs & Pharmaceuticals Business Description
Venmax Drugs & Pharmaceuticals Ltd is engaged in the manufacturing and sale of bulk drugs. The company is engaged in the business of IT & ITES services.
33GF Score
Get the complete analysis for BOM:531015
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531015 has been successfully added to your 
